SCHEDULE: KPCB Funds Exit Sagimet Biosciences Stake
Schedule 13G Amendment (Early Exit Filing)
KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC have filed an early exit Schedule 13G, reporting zero beneficial ownership in Sagimet Biosciences Inc. due to their planned termination.
Summary
- KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates an early exit by the Reporting Persons, who now beneficially own 0.00 shares, representing 0.0% of Sagimet Biosciences Inc.'s Series A Common Stock.
- The reason for the early exit filing is the planned termination and cancellation of both KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC in Delaware before year-end 2025.
Sentiment
Score: 5
Explanation: The filing is neutral as it is a procedural disclosure of an institutional investor's exit due to its own dissolution, not related to the issuer's performance or prospects.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding Sagimet Biosciences Inc.'s operations or financial performance. It solely pertains to the exit of the reporting entities.
Industry Context
This filing reflects a procedural change in institutional ownership rather than a direct commentary on Sagimet Biosciences Inc.'s industry position or performance. The exit of the KPCB funds is attributed to their own dissolution, not specific issues with Sagimet.
Stakeholder Impact
- Shareholders of Sagimet Biosciences Inc. will note the exit of KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC as beneficial owners, which may slightly alter the institutional ownership profile.
Next Steps
- The planned termination and cancellation of KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC in Delaware before year-end 2025.
Key Dates
| Date | Description |
|---|---|
| 12/17/2025 | Signature date of the Schedule 13G filing by Susan Biglieri, Chief Financial Officer for both Reporting Persons. |
| 12/18/2025 | Date of event which required the filing of this statement. |
| before year-end 2025 | Planned termination and cancellation of the Reporting Persons in Delaware. |
Keywords
Sagimet Biosciences, KPCB, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Stock Ownership, Investment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.